This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
APICA: Difference between revisions
>Unity Clarified |
>Unity patch |
||
| Line 1: | Line 1: | ||
{{proofread}} | {{headerpanel|{{approval}}{{proofread}}}} | ||
{{SubstanceBox/2NE1}} | {{SubstanceBox/2NE1}} | ||
| Line 15: | Line 15: | ||
==Pharmacology== | ==Pharmacology== | ||
Pharmacological studies of 2NE1 report EC<sub>50</sub> values of 6.89 ± 0.11nM at CB1 and 7.54 ± 0.11nM at CB2. These values are fairly close to those found for Δ9-[[THC]], although 2NE1 is a full agonist at both receptors, while Δ9-THC is a partial agonist.<ref>Samuel D. Banister, Jordyn Stuart, Richard C. Kevin, Amelia Edington, Mitchell Longworth, Shane M. Wilkinson, Corinne Beinat, Alexandra S. Buchanan, David E. Hibbs, Michelle Glass, Mark Connor, Iain S. McGregor, and Michael Kassiou. "Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135" Chemical Neuroscience (2015). 6(8). 1445-1458. doi:10.1021/acschemneuro.5b00107</ref> It is likely that 2NE1 shares many of the in vivo properties of [[Δ9-THC]]. However, the role of these interactions and how they result in the cannabinoid high | Pharmacological studies of 2NE1 report EC<sub>50</sub> values of 6.89 ± 0.11nM at CB1 and 7.54 ± 0.11nM at CB2. These values are fairly close to those found for Δ9-[[THC]], although 2NE1 is a full agonist at both receptors, while Δ9-THC is a partial agonist.<ref>Samuel D. Banister, Jordyn Stuart, Richard C. Kevin, Amelia Edington, Mitchell Longworth, Shane M. Wilkinson, Corinne Beinat, Alexandra S. Buchanan, David E. Hibbs, Michelle Glass, Mark Connor, Iain S. McGregor, and Michael Kassiou. "Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135" Chemical Neuroscience (2015). 6(8). 1445-1458. doi:10.1021/acschemneuro.5b00107</ref> It is likely that 2NE1 shares many of the in vivo properties of [[Δ9-THC]]. However, the role of these interactions and how they result in the cannabinoid high has yet to be scientifically validated. | ||
==Subjective effects== | ==Subjective effects== | ||
| Line 48: | Line 48: | ||
Anecdotal reports which describe the effects of this compound within our [[experience index]] include: | Anecdotal reports which describe the effects of this compound within our [[experience index]] include: | ||
{{#ask: [[Category:2NE1]][[Category:Experience]]|format=ul|Columns=1}} | {{#ask: [[Category:2NE1]][[Category:Experience]]|format=ul|Columns=1}} | ||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
{{further|Synthetic cannabinoid#Toxicity and harm potential|Research chemicals#Toxicity and harm potential}} | {{further|Synthetic cannabinoid#Toxicity and harm potential|Research chemicals#Toxicity and harm potential}} | ||
| Line 68: | Line 65: | ||
==Legal issues== | ==Legal issues== | ||
{{ | {{legalStub}} | ||
*'''United Kingdom''' - 2NE1 is a class B drug under the third-generation synthetic cannabinoids generic definition, which came into effect on the 14th December 2016 and is illegal to possess, produce, supply, or import. <ref>The Misuse of Drugs Act 1971 (Amendment) Order 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2016/1109/made</ref> | *'''United Kingdom''' - 2NE1 is a class B drug under the third-generation synthetic cannabinoids generic definition, which came into effect on the 14th December 2016 and is illegal to possess, produce, supply, or import. <ref>The Misuse of Drugs Act 1971 (Amendment) Order 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2016/1109/made</ref> | ||
*'''China:''' As of October 2015 2NE1 is a controlled substance in China.<ref>关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html</ref> | *'''China:''' As of October 2015 2NE1 is a controlled substance in China.<ref>关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html</ref> | ||
| Line 85: | Line 82: | ||
==References== | ==References== | ||
{{reflist|2}} | |||
[[Category:Psychoactive substance]] | [[Category:Psychoactive substance]] | ||
[[Category:Research chemical]] | [[Category:Research chemical]] | ||
[[Category:Cannabinoid]] | [[Category:Cannabinoid]] | ||